NDLI: Durvalumab in NSCLC: latest evidence and clinical potential

Please wait, while we are loading the content...

Durvalumab in NSCLC: latest evidence and clinical potential

Content Provider	SAGE Publishing
Author	Muñoz-Unceta, Nerea Burgueño, Isabel Jiménez, Elizabeth Paz-Ares, Luis
Copyright Year	2018
Abstract	Advances in immunotherapy have led to radical improvements in outcomes, including overall survival, such as in non-small cell lung cancer (NSCLC) patients with metastatic disease treated with immune checkpoint inhibitors. More recently, promising results have been obtained in earlier disease settings, and combinations with other therapies are being actively investigated. Durvalumab, a monoclonal antibody directed against the programmed death ligand 1, has demonstrated significant activity in NSCLC, including increased progression-free survival rates after chemoradiation for unresectable stage III disease, with a favourable safety profile. Clinical trials, including phase III studies, are ongoing as monotherapy and in combination with chemotherapy, radiotherapy and other immunotherapies, such as the anti-cytotoxic T-lymphocyte antigen 4 drug tremelimumab, in diverse stages of the disease.
Related Links	https://journals.sagepub.com/doi/pdf/10.1177/1758835918804151?download=true
ISSN	17588359
Volume Number	10
Journal	Therapeutic Advances in Medical Oncology (TAM)
e-ISSN	17588359
DOI	10.1177/1758835918804151
Language	English
Publisher	Sage Publications UK
Publisher Date	2018-10-11
Publisher Place	London
Access Restriction	Open
Rights Holder	© The Author(s), 2018
Subject Keyword	tumour mutational burden PD-L1 expression testing immunotherapy predictive biomarker radiotherapy lung cancer checkpoint inhibitors
Content Type	Text
Resource Type	Article
Subject	Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

PD-L1 expression testing in non-small cell lung cancer

Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC

PD-L1 expression on tumor cells as a potential predictive biomarker for patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab.

Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies

Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors

GEO Data Mining Identifies OLR1 as a Potential Biomarker in NSCLC Immunotherapy

Heterogeneity of tumour mutational burden in metastatic NSCLC demonstrated by endobronchial ultrasound sampling

Blood Tumor Mutational Burden as a Predictive Biomarker in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.

Durvalumab in NSCLC: latest evidence and clinical potential

Similar Documents

PD-L1 expression testing in non-small cell lung cancer

Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC

PD-L1 expression on tumor cells as a potential predictive biomarker for patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab.

Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies

Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors

GEO Data Mining Identifies OLR1 as a Potential Biomarker in NSCLC Immunotherapy

Heterogeneity of tumour mutational burden in metastatic NSCLC demonstrated by endobronchial ultrasound sampling

Blood Tumor Mutational Burden as a Predictive Biomarker in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.

Durvalumab in NSCLC: latest evidence and clinical potential